Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | TERT | O14746 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | PPARD | Q03181 | 3/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | TOP1 | P11387 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910291 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL8813801 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL1740121 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL1739857 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL1738577 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL7300136 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL38571 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL3689073 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL8813806 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG | |
| SCHEMBL910387 | 1.00 | FAAH (0.58) | FAAHTRPV1TERTPTPN1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | claimed |
| EP-2262763-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2010-12-22 | — | — | EP | claimed |
| WO-2009109973-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2009-09-11 | — | — | WO | claimed |
| US-9428448-B2 | Compounds and methods of treating obesity | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | disclosed |
| EP-2262763-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009109973-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2009-09-11 | — | — | WO | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | FABP4, LIPC, GPR119 | FAAH 116/4885TRPV1 2146/4885TERT 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.